Q4 2024 Earnings Call Transcript February 11, 2025 Edwards Lifesciences Corporation beats earnings expectations. Reported EPS ...

Canaccord raised the firm’s price target on Edwards Lifesciences (EW) to $71 from $66 and keeps a Hold rating on the shares. The firm said they ...

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

Evercore ISI analyst Vijay Kumar maintained a Hold rating on Edwards Lifesciences (EW – Research Report) today and set a price target of ...

Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

The latest conference call transcript from Edwards Lifesciences Corporation has revealed a remarkable fourth quarter ...

Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

Scott Ullem; Chief Financial Officer, Corporate Vice President; Edwards Lifesciences Corp Daveen Chopra; Corporate Vice President - Surgical Structural Heart; Edwards Lifesciences Corp Larry Wood; ...

Edwards Lifesciences Corporation (NYSE:EW) develops medical innovations for heart disease and critical care monitoring. Its ...

Bleakley Financial Group LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 5.3% during the 4th ...